Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201

NCT00230490 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

150

Enrollment

INDUSTRY

Sponsor class

Stopped Adverse findings from nonclinical carcinogenicity studies.

Conditions

Hepatitis B, Chronic

Interventions

DRUG: pradefovir mesylate
DRUG: adefovir dipivoxyl

Sponsor

Bausch Health Americas, Inc.